HCV and Co-morbid Alcohol Use Disorders: A Translational Investigation of Antiviral Therapy Outcomes on CNS Function

CompletedOBSERVATIONAL
Enrollment

63

Participants

Timeline

Start Date

May 16, 2019

Primary Completion Date

October 31, 2023

Study Completion Date

December 29, 2023

Conditions
Hepatitis CAlcohol Use Disorder
Interventions
DIAGNOSTIC_TEST

Neuropsychological assessment

Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later).

BEHAVIORAL

Neuroimaging

Subjects, well characterized with respect to their substance use, will be evaluated with functional magnetic resonance imaging (fMRI) tasks, resting state MRI (rsMRI), high resolution anatomical MRI, standard diffusion weighted imaging (DWI) and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.

Trial Locations (1)

97207-2964

VA Portland Health Care System, Portland, OR, Portland

All Listed Sponsors
lead

VA Office of Research and Development

FED

collaborator

Oregon Health and Science University

OTHER

collaborator

Portland VA Medical Center

FED

NCT03902366 - HCV and Co-morbid Alcohol Use Disorders: A Translational Investigation of Antiviral Therapy Outcomes on CNS Function | Biotech Hunter | Biotech Hunter